List of Excipients in Branded Drug PREVYMIS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	CARNAUBA WAX	2031-08-30
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	CELLULOSE, MICROCRYSTALLINE	2031-08-30
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	CROSCARMELLOSE SODIUM	2031-08-30
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	FERRIC OXIDE YELLOW	2031-08-30
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	HYPROMELLOSE 2910	2031-08-30
Merck Sharp & Dohme LLC	PREVYMIS	letermovir	0006-3075	LACTOSE MONOHYDRATE	2031-08-30

PREVYMIS Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

PREVYMIS, Merck’s letermovir product, uses a differentiated excipient strategy across tablet, oral-solution and intravenous presentations. The commercial opportunity is strongest in excipient supply, transplant-focused delivery systems, pediatric and swallowing-friendly dosage forms, and manufacturing services rather than in direct substitution for the branded product. Because letermovir is a small molecule, biosimilar risk does not apply; generic entry will depend on abbreviated new drug applications, patent certifications, formulation equivalence and regulatory exclusivity.

What is PREVYMIS and how is it administered?

PREVYMIS contains letermovir, a human cytomegalovirus, or CMV, terminase-complex inhibitor. The FDA approved it in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem-cell transplant. FDA later expanded the product to include prophylaxis in adult kidney-transplant recipients at high risk, defined as donor CMV-seropositive and recipient CMV-seronegative status.[1]

PREVYMIS is marketed in three clinically relevant presentations:

Presentation	Strength	Administration	Commercial role
Film-coated tablet	240 mg	Oral, once daily	Primary outpatient presentation
Film-coated tablet	480 mg	Oral, once daily	Primary adult maintenance presentation
Oral solution	240 mg per 12 mL	Oral, once daily	Patients unable to swallow tablets
Injection	240 mg per 12 mL	Intravenous infusion	Hospital use when oral administration is not feasible

The recommended adult dose is generally 480 mg once daily. The dose is reduced to 240 mg once daily when co-administered with cyclosporine because cyclosporine increases letermovir exposure.[1]

The product is used for prolonged prophylaxis in transplant populations. That duration supports demand for stable oral formulations, reliable excipient sourcing and dosage forms that can accommodate complex medication regimens.

What excipients are used in PREVYMIS formulations?

PREVYMIS uses conventional solid-dose excipients in the tablets and a solubilizing cyclodextrin system in the liquid and intravenous products. The formulation architecture reflects two different technical requirements: compact oral tablets for routine use and aqueous delivery for patients who cannot take tablets.

PREVYMIS tablet excipients

The tablet formulation uses standard pharmaceutical excipient classes, including:

• Microcrystalline cellulose as a diluent and compression aid.
• Croscarmellose sodium as a disintegrant.
• Povidone as a binder.
• Magnesium stearate as a lubricant.
• Film-coating excipients, including hypromellose and colorant components.
• Lactose-containing coating or formulation components, as identified in the FDA prescribing information.[1]

These materials are widely available and are not, by themselves, a major barrier to generic development. The commercial value lies in grade selection, particle-size control, lubrication performance, coating robustness, content uniformity and stability rather than in simple ownership of the excipient names.

PREVYMIS oral solution and injection

The oral solution and injection use hydroxypropyl betadex, a hydroxypropylated beta-cyclodextrin, to improve the aqueous formulation of letermovir. The products also use pH-adjusting components and aqueous vehicle systems appropriate to the route of administration.[1]

Hydroxypropyl betadex is strategically important because it affects:

• Drug solubilization.
• Solution stability.
• Osmolality.
• Infusion tolerability.
• Container compatibility.
• Manufacturing cost.
• Supply-chain resilience.

Cyclodextrin-based formulations can create greater technical and commercial complexity than conventional tablets. Suppliers must demonstrate pharmaceutical grade, impurity control, microbiological quality, residual solvent control and consistent substitution characteristics.

Why is the PREVYMIS excipient strategy commercially relevant?

The formulation strategy creates opportunities across the product lifecycle, even where the core excipients are not proprietary.

Long-duration prophylaxis increases formulation requirements

Patients may receive PREVYMIS for weeks or months after transplantation. A long treatment course increases the importance of:

• Tablet swallowability.
• Dose flexibility.
• Low gastrointestinal burden.
• Consistent dissolution.
• Packaging protection.
• Medication adherence.
• Availability during inpatient-to-outpatient transitions.

A supplier that can improve tablet robustness, reduce friability or support smaller tablets could target transplant hospitals and specialty pharmacies without changing the active pharmaceutical ingredient.

Intravenous and oral dosage forms create a dual-supply model

The oral and injectable products do not use the same excipient platform. This creates separate procurement opportunities:

1. Tablet excipients and coating systems.
2. Cyclodextrin and parenteral excipient systems.
3. Sterile manufacturing components.
4. Container-closure systems.
5. Infusion-compatible packaging.
6. Analytical testing for extractables, leachables and particulate matter.

The intravenous product has higher technical barriers because the manufacturer must control sterility, endotoxin levels, particulate contamination, pH, osmolality and infusion compatibility.

Cyclodextrin supply is a potential bottleneck

Hydroxypropyl betadex is more specialized than microcrystalline cellulose, magnesium stearate or common tablet disintegrants. Commercial opportunities include:

• Secondary sourcing.
• Regional manufacturing.
• Pharmaceutical-grade purification.
• Improved lot-to-lot substitution control.
• Lower-cost equivalents with comparable safety profiles.
• Long-term supply agreements with injectable manufacturers.

The relevant commercial question is not whether hydroxypropyl betadex is chemically unique. It is whether a second supplier can qualify material without changing the finished-product profile or triggering extensive comparability work.

What formulation patents protect PREVYMIS?

The main patent value around PREVYMIS is expected to reside in letermovir composition, therapeutic use and formulation claims, but the legal scope must be assessed patent by patent. FDA labeling does not define patent ownership or claim coverage.

The relevant patent categories are:

Patent category	Potential relevance to PREVYMIS	Generic or competing-product impact
Composition-of-matter patents	Protect letermovir or related chemical entities	Usually the strongest barrier to direct generic entry
Salt, polymorph or crystalline-form patents	Protect a particular solid form or chemical presentation	May affect API sourcing and bioequivalence
Formulation patents	Cover cyclodextrin solutions, tablet composition or stability systems	Can create design-around obligations
Method-of-use patents	Cover CMV prophylaxis in defined transplant populations	Can affect labeling and induced-infringement risk
Manufacturing patents	Cover synthesis, purification or process conditions	May limit API routes but often allow alternative processes
Packaging or container patents	Cover stability or administration configurations	Usually narrower commercial impact

A generic manufacturer does not necessarily need to copy every branded excipient. It can use a different formulation if the product meets applicable bioequivalence, quality and stability requirements and does not infringe enforceable claims.

Patent risk is therefore highest where claims cover the active ingredient, a necessary solid form or a clinically important use. Excipient substitution is more commercially useful when it also avoids formulation claims or reduces dependence on protected manufacturing steps.

When does PREVYMIS lose exclusivity?

PREVYMIS does not have biosimilar exclusivity because letermovir is a small molecule. Market entry would normally proceed through the ANDA pathway rather than the biosimilar pathway.

The principal exclusivity milestones are:

Milestone	Status
FDA approval	2017
New chemical entity exclusivity	Initially applied to the new active ingredient
Orphan-drug-related protections	May apply to the qualifying transplant indications and must be assessed by indication
Patent exclusivity	Depends on issued patents, terminal disclaimers, pediatric extensions and litigation outcomes
Generic pathway	ANDA with Paragraph IV or other applicable certification
Biosimilar pathway	Not applicable

FDA statutory exclusivity and patent term are separate. A generic applicant may submit an ANDA before patent expiry with a Paragraph IV certification. Commercial launch can still be delayed by patent litigation, a 30-month stay, settlement terms or an injunction.[2]

A precise launch date cannot be inferred from the brand approval date alone. The relevant analysis requires the current Orange Book patent listing, patent-term adjustment, pediatric exclusivity and any court decisions or settlements.

What is the Orange Book status of PREVYMIS?

PREVYMIS is an FDA-approved small-molecule drug and its relevant patent information is evaluated through the FDA Orange Book framework. Orange Book listings may include patents directed to the drug substance, drug product, formulation or approved method of use.[2]

The practical diligence points are:

• Confirm every listed patent and expiration date.
• Separate active patents from expired or delisted patents.
• Review use codes tied to transplant populations.
• Check whether any patent has pediatric exclusivity added to its term.
• Review Paragraph IV notices and district-court complaints.
• Identify whether an ANDA applicant has carved out a patented method of use.
• Compare listed patents with the actual label and dosage forms.

Orange Book status should not be treated as a complete map of all possible patent risk. Unlisted process patents, foreign patents, trade secrets and regulatory exclusivity can still affect commercial entry.

Which companies are challenging PREVYMIS?

Publicly visible generic competition must be assessed through FDA ANDA records, Paragraph IV litigation databases and district-court filings. No broad biosimilar competition is expected because letermovir is not a biologic.

Potential challengers are likely to include:

• Large generic manufacturers with transplant or infectious-disease portfolios.
• Specialty generic companies capable of developing complex oral liquids.
• Manufacturers with cyclodextrin-based injectable experience.
• API suppliers seeking vertical integration into finished dosage forms.
• Regional companies targeting jurisdictions where relevant patents have expired.

The most credible challenger may not be the company with the lowest tablet manufacturing cost. It may be the company capable of qualifying an oral solution or intravenous alternative while managing cyclodextrin sourcing and regulatory comparability.

How strong is the PREVYMIS patent estate?

The estate should be viewed as stronger for the active ingredient and approved clinical use than for ordinary tablet excipients.

Relative strength by technology area

Technology area	Expected strategic strength	Reason
Letermovir active ingredient	High, subject to current patent status	Direct substitution is difficult before composition expiry
CMV prophylaxis use	Moderate to high	Can affect label strategy and carve-outs
Cyclodextrin formulation	Moderate	May create technical and legal barriers for liquid or injectable copies
Conventional tablet excipients	Low to moderate	Many design-around options exist
Manufacturing process	Moderate	Alternative API routes may be possible
Packaging and stability	Low to moderate	Important for quality, but often design-around capable

The branded company’s commercial protection also comes from clinical familiarity, transplant-center protocols, physician confidence and integration into post-transplant care. Those factors are not patents, but they can slow switching after generic entry.

What generic launch scenarios exist for PREVYMIS?

Three launch scenarios are commercially relevant.

Full-label generic launch

A generic applicant obtains approval for the tablet and retains the approved transplant indications. This is the highest-impact scenario because it directly competes with the core outpatient product.

Carved-out label launch

The applicant omits a patented method of use from its labeling. This can permit entry while limiting promotion for the protected indication. Hospital protocols and prescribing practices determine whether the carve-out materially reduces commercial access.

Alternative-presentation launch

A company launches an oral solution, injectable product or different tablet strength after obtaining the necessary approval. This could target patients who cannot swallow tablets or require inpatient administration.

A differentiated generic may compete through:

• Lower unit cost.
• Hospital contracting.
• Oral-solution availability.
• Reduced excipient burden.
• Smaller tablet size.
• More flexible packaging.
• Regional distribution.

What commercial opportunities exist in PREVYMIS excipients?

The most credible opportunities are in supply, qualification and lifecycle support.

Pharmaceutical-grade cyclodextrin

A qualified hydroxypropyl betadex supplier could target Merck, contract manufacturers and future generic applicants. The value proposition would include dual sourcing, regulatory documentation, consistent substitution and validated impurity profiles.

Pediatric and swallowing-friendly dosage forms

CMV prophylaxis is concentrated in transplant populations, including patients with difficulty swallowing. Opportunities include:

• Ready-to-use oral liquids.
• Lower-volume concentrates.
• Unit-dose oral syringes.
• Flavored formulations.
• Dispersible tablets.
• Smaller tablets with equivalent exposure.

Any new pediatric presentation would require clinical and regulatory support. Excipient safety, dosing accuracy and administration-device compatibility would be central.

Hospital-ready packaging

Commercial opportunities include:

• Ready-to-administer infusion bags.
• Unit-dose packaging.
• Light-protective containers.
• Improved cold-chain or room-temperature stability.
• Barcoded transplant-center packaging.
• Reduced preparation steps for pharmacy staff.

Excipient and process optimization

Manufacturers can reduce cost through:

• Better-flowing tablet blends.
• Lower lubricant use.
• Faster coating cycles.
• More efficient cyclodextrin dissolution.
• Reduced solution hold times.
• Improved filtration and filling yields.

These improvements must preserve dissolution, assay, impurities, sterility and stability specifications.

How does PREVYMIS compare with competing CMV therapies?

PREVYMIS has a different formulation and safety profile from older CMV agents such as ganciclovir, valganciclovir and foscarnet.

Product	Active ingredient	Main formulation profile	Commercial distinction
PREVYMIS	Letermovir	Tablet, oral solution, injection; cyclodextrin-based liquid systems	CMV prophylaxis with a distinct safety and interaction profile
Valcyte	Valganciclovir	Tablet and oral solution	Broad historical use; hematologic toxicity is a key clinical consideration
Cytovene-IV	Ganciclovir	Intravenous	Hospital-based antiviral therapy
Foscavir	Foscarnet	Intravenous solution	Complex administration and renal-toxicity considerations

PREVYMIS is not a direct excipient substitute for these products. Its commercial position depends on prophylaxis, transplant protocols, drug-interaction management and payer access.

What litigation and settlement issues affect PREVYMIS?

Relevant litigation questions include:

• Whether an ANDA applicant filed a Paragraph IV certification.
• Whether Merck sued within the statutory period.
• Whether a 30-month stay applies.
• Whether the case ended in settlement.
• Whether the settlement permits an agreed launch date.
• Whether the settlement includes authorized-generic or supply terms.
• Whether method-of-use claims were carved out.
• Whether a court narrowed or invalidated key claims.

Settlement terms are often confidential or only partly disclosed. A generic launch date stated in a settlement may not equal the earliest possible entry if pediatric exclusivity, regulatory deficiencies or manufacturing constraints remain.

Key Takeaways

• PREVYMIS uses conventional tablet excipients and a more specialized hydroxypropyl-betadex platform for oral solution and intravenous delivery.
• The largest excipient opportunity is pharmaceutical-grade cyclodextrin supply, qualification and secondary sourcing.
• Tablet excipients are generally design-around capable and are unlikely to provide the main long-term barrier to generic entry.
• Oral-solution and injectable alternatives have greater technical complexity than conventional tablets.
• Letermovir is a small molecule, so biosimilar competition does not apply.
• Generic entry will depend on Orange Book patents, Paragraph IV certifications, method-of-use claims, litigation and settlement terms.
• Commercial opportunities include pediatric dosage forms, swallowing-friendly delivery, hospital packaging and excipient-process optimization.
• The strongest intellectual-property protection is likely to relate to letermovir, clinical use and selected formulation or manufacturing claims, not ordinary excipient selection.

FAQs

Is hydroxypropyl betadex the main differentiated excipient in PREVYMIS?

Yes. It is the key specialized solubilizing excipient in the oral-solution and intravenous presentations. Its pharmaceutical-grade quality and supply continuity are more commercially significant than the tablet’s standard excipients.

Can a generic PREVYMIS use different excipients?

Yes, if the generic meets FDA quality and bioequivalence requirements and does not infringe enforceable formulation or manufacturing claims. Different excipients may affect dissolution, stability, impurity formation and regulatory comparability.

Does PREVYMIS have biosimilar competition?

No. Letermovir is a small-molecule active ingredient. Competition would proceed through generic-drug pathways, primarily an ANDA rather than a biosimilar application.

Could a new PREVYMIS oral liquid support pediatric expansion?

Potentially. A new oral liquid could improve administration for children or adults unable to swallow tablets, but it would require appropriate regulatory support, dosing accuracy, excipient safety and stability data.

What is the most attractive supplier opportunity around PREVYMIS?

A qualified, redundant supply of pharmaceutical-grade hydroxypropyl betadex combined with formulation-development and regulatory-support capabilities is the strongest identifiable opportunity. Secondary opportunities exist in oral-liquid delivery devices, hospital-ready packaging and transplant-focused generic manufacturing.

References

1. U.S. Food and Drug Administration. (2024). PREVYMIS (letermovir) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2017). FDA approves new drug to prevent CMV infection after transplant. https://www.fda.gov

4. European Medicines Agency. (2018). Prevymis: EPAR - product information. https://www.ema.europa.eu

5. Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.